This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. MENS, GMTX, MOR, ZYME, CALT, MBX, ETHZ, SBTX, AVTE, and BIOAShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Jyong Biotech (MENS), Gemini Therapeutics (GMTX), MorphoSys (MOR), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), MBX Biosciences (MBX), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), and BioAge Labs (BIOA). Cerecor vs. Its Competitors Jyong Biotech Gemini Therapeutics MorphoSys Zymeworks Calliditas Therapeutics AB (publ) MBX Biosciences Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics BioAge Labs Jyong Biotech (NASDAQ:MENS) and Cerecor (NASDAQ:CERC) are both pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Does the media prefer MENS or CERC? In the previous week, Jyong Biotech had 4 more articles in the media than Cerecor. MarketBeat recorded 4 mentions for Jyong Biotech and 0 mentions for Cerecor. Jyong Biotech's average media sentiment score of 0.62 beat Cerecor's score of 0.16 indicating that Jyong Biotech is being referred to more favorably in the media. Company Overall Sentiment Jyong Biotech Positive Cerecor Neutral Is MENS or CERC more profitable? Jyong Biotech has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Jyong Biotech's return on equity of 0.00% beat Cerecor's return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Cerecor -1,194.82%-261.82%-133.96% Do analysts recommend MENS or CERC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cerecor 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of MENS or CERC? 62.8% of Cerecor shares are owned by institutional investors. 45.7% of Cerecor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, MENS or CERC? Jyong Biotech has higher earnings, but lower revenue than Cerecor. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/ACerecor$6.70M214.52-$63.50M-$0.57-26.26 SummaryJyong Biotech beats Cerecor on 6 of the 9 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$1.03B$6.12B$10.63BDividend YieldN/A4.84%5.66%4.71%P/E Ratio-26.261.1364.0822.83Price / Sales214.5229.35612.79132.68Price / CashN/A17.6438.5062.09Price / Book68.057.3112.726.53Net Income-$63.50M-$7.96M$3.30B$275.96M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$14.97+5.3%N/A+47.7%$1.44B$6.70M-26.2631MENSJyong BiotechN/A$47.68+21.1%N/AN/A$3.63BN/A0.0031Analyst ForecastGap DownGMTXGemini TherapeuticsN/A$66.08+1.6%N/A+46.7%$2.86BN/A-66.0830MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ZYMEZymeworks2.0543 of 5 stars$17.10+0.1%$21.43+25.3%+32.9%$1.29B$122.87M-11.44460Trending NewsAnalyst ForecastAnalyst RevisionGap UpCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MBXMBX BiosciencesN/A$17.94+2.5%$39.88+122.3%N/A$603.68MN/A-3.9636ETHZFlag Ship AcquisitionN/A$2.45+1.7%N/AN/A$402.85MN/A-0.167News CoverageAnalyst ForecastSBTXSilverback TherapeuticsN/A$10.05+3.4%N/A-19.0%$362.38MN/A-4.1583High Trading VolumeAVTEAerovate TherapeuticsN/A$8.63+0.1%N/A-87.3%$250.14MN/A-2.8920Gap UpHigh Trading VolumeBIOABioAge Labs0.172 of 5 stars$5.86-0.3%N/AN/A$210.08MN/A0.00N/ANews CoverageAnalyst Forecast Related Companies and Tools Related Companies Jyong Biotech Alternatives Gemini Therapeutics Alternatives MorphoSys Alternatives Zymeworks Alternatives Calliditas Therapeutics AB (publ) Alternatives MBX Biosciences Alternatives Flag Ship Acquisition Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
